Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Prostate-associated antigens and vaccine-based immunotherapy regimens

Prostate-associated antigens and vaccine-based immunotherapy regimens

US Patent 9468672 · Granted Oct 18, 2016

Estimated economic value: $376,037,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Alphavirus neoantigen vectors2024
Modified adenoviruses2024
Multiepitope vaccine cassettes2023
Modified adenoviruses2023
Recombinant vaccinia virus and methods of use thereof2022
Alphavirus antigen vectors2022
Alphavirus neoantigen vectors2022
Anti-PD-1 antibodies and methods of use thereof2022
Anti-PD-1 antibodies and methods of use thereof2022
Vectors for expression of prostate-associated antigens2021
Prostate-associated antigens and vaccine-based immunotherapy regimens2021
Prostate-associated antigens and vaccine-based immunotherapy regimens2021